Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlargine

    Glargine

    Jump to

    • To cut healthcare costs, US must partner India: Biocon's Shaw

      Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.

    • Speciality offers better returns, says Biocon Chief

      Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.

    • Trastuzumab marketing approval may come in 12-18 months: Biocon

      The European Medicines Agency (EMA) has accepted to review Mylan and Biocon‘s application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.

    • Biocon Q1 net seen down 5%, contract research may drive revenue

      Factors to watch out for in Q1 would be margin, contract research business, R&D cost, pricing pressure in legacy API biz (especially statins), recovery in branded formulation (was flat in Q4 due to restructuring) and pick up in Middle East market (did well in Q4).

    • Biocon's partner firm launches diabetes product in Japan

      "Close on the heels of receiving approval for its Insulin Glargine from the Japanese regulator last year, its partner Fujifilm Pharma Co has launched the product in Japan today," Biocon said in a BSE filing.

    • US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw

      These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.

    • Biosimilar insulin Glargine to make $100 m from FY18: Biocon

      Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.

    • Biocon up 7% on Morgan Stanley upgrade, 2016 likely to be strong

      It believes that Biocon's (and its partner Mylan) four potential product filings each in the US and EU would add credibility to its pipeline and bring market recognition. Emerging market monetisation is under way, but the US and EU opportunities will take at least two years, according to report.

    • Biocon gets approval for insulin Glargine in Mexico

      The company's insulin Glargine has been approved by Cofepris, the Mexican health authority, through its Mexican partner PiSA Farmaceutica (PiSA), Biocon said in a statement.

    • Biocon up 3% post Mylan's phase-3 trials for Glargine

      Kiran Mazumdar Shaw, CMD of the company sees it to be a huge opportunity in the diabetic market and expects the insulin analogue market to grow in double-digits.

    • Biocon-Mylan start phase-3 global trials for drug Glargine

      The size of Glargine is expected to be around USD 3-4 billion globally.

    • Biocon shrs rise on insulin products deal with Mylan

      Biocon shares rose 2 percent in morning trade on Thursday after the biotechnology company said it has enhanced its partnership with pharma major Mylan through a strategic collaboration for insulin products.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347